Finanzen von Iterum Therapeutics PLC (ITRM)ITRMIterum Therapeutics PLC

Evaluating the bottom line, Iterum Therapeutics PLC maintains a gross margin of 5.38%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1982.31%, while the net margin is -2302.31%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ITRM converts its operational activities into shareholder value.

In the context of the broader market, ITRM competes directly with industry leaders such as INM and HELP. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, ITRM's gross margin of 5.38% stands against INM's N/A and HELP's N/A. Such benchmarking helps identify whether Iterum Therapeutics PLC is trading at a premium or discount relative to its financial performance.

In Q3 2025, revenue remained flat at $390,000 YoY. Net income improved to -$8,979,000, up 47.34% YoY, but the company is still operating at a significant loss. EPS dropped to -0.2, down 33.33% YoY, indicating worsening shareholder returns. Gross margin remained flat at 5.38%. Overall, the financials show no significant growth and highlight ongoing financial struggles.